Dyne Therapeutics 40% Rally Faces Fund Selloff Questions
A dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
Easy expense tracking combines automation, simple categorization, and a minimal workflow to keep your finances accurate without the hassle.
13,940 articlesA dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
Investors eye Xcel Brands (XELB) 2026 as it reports Q1 results. This guide explains what to look for in the transcrip...
Imagine a world where your phone pays you back for every scroll and tap. This article dives into Mode Mobile, a specu...
A decade-long track record of dividend growth has helped Vanguard Dividend Appreciation ETF outpace many high-yield r...
Bitcoin’s trade flips bond as the bond market takes control of financial conditions, signaling a pivot from easy-mone...
When a major hedge fund trims a stake in a diversified telecom, it sends a message to the market. This article breaks...
Zscaler is set to report Q3 after the close on May 28, 2026, with analysts eyeing ARR growth, AI monetization progres...
GraniteShares’ 2x COIN ETF has seen substantial NAV erosion as Coinbase volatility spikes, prompting renewed debate o...
As the semiconductor cycle broadens, investors are flocking to TSMC on its diversified AI chip manufacturing capabili...
Kohl's stunned investors with a strong swing in its latest quarterly results, sending the stock higher by double digi...
Investors watched AST SpaceMobile tumble on launch-delay fears after a Blue Origin test setback. This piece breaks do...
A practical, reader-friendly guide to interpreting Xunlei's Q1 2026 earnings. Learn what to watch, how to model resul...